525 related articles for article (PubMed ID: 35450208)
21. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman RJ; Arons E
Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
24. Hairy cell leukemia: a brief update on current knowledge and treatment prospects.
Puła A; Robak T
Curr Opin Oncol; 2021 Sep; 33(5):412-419. PubMed ID: 34264896
[TBL] [Abstract][Full Text] [Related]
25. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
26. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Rogers KA; Andritsos LA; Wei L; McLaughlin EM; Ruppert AS; Anghelina M; Blachly JS; Call T; Chihara D; Dauki A; Guo L; Ivy SP; James LR; Jones D; Kreitman RJ; Lozanski G; Lucas DM; Ngankeu A; Phelps M; Ravandi F; Schiffer CA; Carson WE; Jones JA; Grever MR
Blood; 2021 Jun; 137(25):3473-3483. PubMed ID: 33754642
[TBL] [Abstract][Full Text] [Related]
28. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E; Cornet E; Troussard X
Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
[TBL] [Abstract][Full Text] [Related]
29. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
30. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
[TBL] [Abstract][Full Text] [Related]
31. Management of hairy cell leukemia variant.
Robak T
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():53-6. PubMed ID: 21599606
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review.
Sardar M; Malik SU; Khan A; Idrees M; Ahmad Q; Sohail C; Naseer R; Amin S; McBride A; Abuzar M; Safdar A; Chakraborty R; Lee P; Sharon D; Anwer F
J Hematol; 2019 Mar; 8(1):1-10. PubMed ID: 32300434
[TBL] [Abstract][Full Text] [Related]
33. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
34. Advances in the Treatment of Hairy Cell Leukemia Variant.
Tran J; Gaulin C; Tallman MS
Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
[TBL] [Abstract][Full Text] [Related]
35. Update on hairy cell leukemia.
Kreitman RJ; Arons E
Clin Adv Hematol Oncol; 2018 Mar; 16(3):205-215. PubMed ID: 29742076
[TBL] [Abstract][Full Text] [Related]
36. Current and emerging treatment options for hairy cell leukemia.
López-Rubio M; Garcia-Marco JA
Onco Targets Ther; 2015; 8():2147-56. PubMed ID: 26316784
[TBL] [Abstract][Full Text] [Related]
37. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
38. Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
Robak T; Janus A; Jamroziak K; Tiacci E; Kreitman RJ
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34202156
[TBL] [Abstract][Full Text] [Related]
39. Hairy Cell Leukaemia.
Cross M; Dearden C
Curr Oncol Rep; 2020 Apr; 22(5):42. PubMed ID: 32297104
[TBL] [Abstract][Full Text] [Related]
40. New treatment options in hairy cell leukemia with focus on BRAF inhibitors.
Falini B; Tiacci E
Hematol Oncol; 2019 Jun; 37 Suppl 1():30-37. PubMed ID: 31187521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]